Precision Diagnostics Market Size worth USD 138.85 billion in 2028 | Exhibiting a CAGR of 12.6%
January 31, 2022 05:55 ET
|
Fortune Business Insights
Pune, India, Jan. 31, 2022 (GLOBE NEWSWIRE) -- The global precision diagnostics market size was USD 54.05 billion in 2020. The market is expected to grow from USD 60.35 billion in 2021 to USD 138.85...
4D Path, University of Leeds Extend Contract to Collaboratively Validate New Technology to Help Doctors More Accurately Diagnose Breast Cancer
March 16, 2021 10:00 ET
|
4D Path
NEWTON, Mass., March 16, 2021 (GLOBE NEWSWIRE) -- 4D Path, creator of a patented computer-aided cancer diagnostic and precision oncology platform, has extended its existing partnership with the...
Dr. Jennifer Levin Carter Joins Advisory Board of Novel Precision Oncology Platform Creator 4D Path
December 15, 2020 10:00 ET
|
4D Path
NEWTON, Mass., Dec. 15, 2020 (GLOBE NEWSWIRE) -- 4D Path, creator of a patented computer-aided cancer diagnostic and precision oncology platform, is pleased to announce that Jennifer Levin Carter,...
4D Path Announces Patented Precision Oncology Platform for Instant Biomarker Profiling and Stratification Just From H&E Biopsy or Resection Images
November 12, 2020 10:00 ET
|
4D Path
NEWTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- 4D Path, a company conceived by an experienced team of scientists, clinicians and management from leading research institutions including MIT,...
[2020-2026] Precision Diagnostics Market Size, Share, Growth, Trends, Revenue, Value, Competitive Landscape, Forecast Report by Fortune Business Insights
September 30, 2020 08:57 ET
|
Fortune Business Insights
Pune, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Developments in The Human Genome Project have given tailwinds to the growth witnessed in the global precision diagnostics market. Fortune Business Insights...
US FDA approves Invivoscribe LeukoStrat CDx FLT3 Mutation Assay as CDx and Astellas drug XOSPATA (gilteritinib fumarate) for treatment of AML patients in the US
November 29, 2018 06:00 ET
|
Invivoscribe, Inc.
SAN DIEGO, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Invivoscribe is pleased to announce FDA approval of both the LeukoStrat CDx FLT3 Mutation Assay and the Astellas drug, XOSPATA (gilteritinib fumarate),...
Invivoscribe Submits LeukoStrat CDx FLT3 Mutation Assay both in the US and Japan to Support Daiichi Sankyo Submissions for Quizartinib
November 27, 2018 06:00 ET
|
Invivoscribe, Inc.
SAN DIEGO, Nov. 27, 2018 (GLOBE NEWSWIRE) -- In support of an ongoing partnership with Daiichi Sankyo, Invivoscribe is pleased to announce submissions of the LeukoStrat® CDx FLT3 Mutation Assay to...
Invivoscribe Submits the LeukoStrat CDx FLT3 Mutation Assay to Support Daiichi Sankyo Submission for Quizartinib in Japan
November 19, 2018 08:00 ET
|
Invivoscribe, Inc.
SAN DIEGO, Nov. 19, 2018 (GLOBE NEWSWIRE) -- In support of an ongoing partnership with Daiichi Sankyo, Invivoscribe is pleased to announce submission of the LeukoStrat® CDx FLT3 Mutation Assay to...